Arcturus Therapeutics (ARCT) Tops Q1 EPS by $1.81

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.87, $1.81 better than the analyst estimate of $0.06. Revenue for the quarter came in at $80.3 million versus the consensus estimate of $37.94 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c